PTAB challenges

Proceedings overview

One AIA trial proceeding has been filed against US patent 12234510. This proceeding reached a status of "Institution Denied," meaning no claims were ever challenged on the merits by the PTAB. This gives a defendant a posture where the patent claims remain untested by this specific IPR.

IPR2025-01353 — Guardant Health, Inc. v. Cold Spring Harbor Laboratory

• Type: Inter Partes Review
• Filed: 2025-07-25
• Status: Institution Denied. This means the PTAB decided not to initiate a trial on the merits of the patentability challenges raised in the petition.
• Judge panel: Not publicly available from the provided data or standard search results without direct access to the PTAB E2E system.
• Petition grounds: Not publicly available from the provided data or standard search results without direct access to the petition itself. IPR petitions typically challenge claims under 35 U.S.C. §§ 102 and/or 103 based on prior art patents and printed publications.
• Institution decision: Denied on 2026-02-18. The PTAB declined to institute the IPR. The specific reasoning for denial would be detailed in the institution decision, which is not available in public search results without direct access to the PTAB E2E portal for this specific case. Common reasons for denial include failing to show a reasonable likelihood that the petitioner would prevail on at least one claim, issues with claim construction, or procedural deficiencies in the petition.
• Final Written Decision: Not issued, as institution was denied.
• Settlement / termination: Not applicable, as institution was denied, and no trial was initiated.
• Appeal: Not applicable, as no Final Written Decision was issued.
• Defensive value: The patent owner, Cold Spring Harbor Laboratory, successfully defended against this IPR petition at the institution stage. This means that, for Guardant Health, Inc. (and its privies), estoppel under 35 U.S.C. § 315(e)(1) applies to the grounds actually raised or that could have been reasonably raised in the petition. For other potential defendants, this specific denial doesn't impact the patentability of the claims on the merits, but it signals that the PTAB found Guardant Health's petition lacking at the threshold.

Strategic summary

All claims of US12234510 remain untested by the PTAB as the sole IPR petition, IPR2025-01353, was denied institution. No claims were canceled, sustained, or modified through this proceeding. Therefore, for most parties, all claims of the patent are still considered viable as far as PTAB proceedings are concerned.

Regarding the estoppel landscape, since IPR2025-01353 was denied institution, statutory estoppel under 35 U.S.C. § 315(e)(1) applies to the petitioner, Guardant Health, Inc., and its privies. This means Guardant Health is barred from asserting in any other proceeding before the Office or in any civil action, any ground that it raised or reasonably could have raised in this IPR petition. For a defendant currently being asserted against by Cold Spring Harbor Laboratory who is not Guardant Health or its privy, all prior-art grounds remain available for potential PTAB challenge. The status of "Institution Denied" itself is not a pattern signal of aggressive PTAB appeals, as no appealable decision was reached. The presence of Guardant Health as a petitioner indicates interest from a significant player in the diagnostics space.

Recommended next steps

If you are a defendant facing assertion of US12234510, the denial of institution for IPR2025-01353 means the patent claims have not been substantively reviewed or narrowed by the PTAB.
You should review the institution decision for IPR2025-01353 to understand the PTAB's specific reasoning for denial. This can provide valuable insight into potential weaknesses of similar petitions or inform strategies for a new petition. Access to this decision would typically be through the USPTO PTAB End-to-End (E2E) system for registered users.
Given the current status, all claims of US12234510 are considered patentable from the perspective of this single PTAB proceeding. If you are considering filing your own IPR, you would need to develop a robust petition that addresses the issues that led to the denial of Guardant Health's petition, ensuring it demonstrates a reasonable likelihood of prevailing on at least one claim.## Proceedings overview
One AIA trial proceeding has been filed against US patent 12234510. This proceeding reached a status of "Institution Denied," meaning the PTAB decided not to initiate a trial on the merits of the patentability challenges raised in the petition. This means no claims were invalidated or sustained. This gives a defendant a posture where the patent claims remain untested by this specific IPR.

IPR2025-01353 — Guardant Health, Inc. v. Cold Spring Harbor Laboratory

• Type: Inter Partes Review
• Filed: 2025-07-25
• Status: Institution Denied (Not Instituted - Merits). This means the PTAB determined that the petition did not meet the threshold requirements for initiating a trial, and thus no claims were reviewed on the merits of patentability.
• Judge panel: The specific judge panel for an institution denial is often not made publicly available in general search results, as the decision may be made by the Director of the USPTO or a delegated panel prior to full Board assignment.
• Petition grounds: The specific claims challenged, prior art references, and statutory bases (§ 102 / § 103 / § 112) raised in the petition are not publicly available from the provided data or standard search results without direct access to the PTAB E2E system. IPR petitions typically challenge claims under 35 U.S.C. §§ 102 (novelty) and/or 103 (obviousness) based on patents and printed publications.
• Institution decision: Denied on 2026-02-18. The PTAB declined to institute the IPR. While the specific reasoning for denial for IPR2025-01353 is not publicly detailed in general search results, institution can be denied for various reasons, including discretionary factors or a failure to demonstrate a reasonable likelihood that the petitioner would prevail on at least one challenged claim. Recent changes in PTAB practice, particularly in 2025, have seen an increase in discretionary denials, with the Director now making initial decisions on discretionary factors before a panel considers the merits. These factors can include "settled expectations" of the patent owner if the petitioner had long-standing knowledge of the patent.
• Final Written Decision: Not issued, as institution was denied.
• Settlement / termination: Not applicable, as institution was denied, and no trial was initiated.
• Appeal: Not applicable, as no Final Written Decision was issued from which to appeal.
• Defensive value: The patent owner, Cold Spring Harbor Laboratory, successfully fended off this IPR petition at the institution stage. This means that, for Guardant Health, Inc. (and its privies), estoppel under 35 U.S.C. § 315(e)(1) applies to the grounds actually raised or that could have been reasonably raised in the petition. For other potential defendants, this specific denial does not impact the patentability of the claims on the merits, but it does indicate that the PTAB found Guardant Health's petition lacking at the preliminary stage.

Strategic summary

All claims of US12234510 remain untested by the PTAB as the sole IPR petition, IPR2025-01353, was denied institution. Therefore, no claims were canceled, sustained, or modified by this proceeding. As a result, for most parties, all claims of the patent are still considered valid and enforceable from a PTAB trial perspective.

Regarding the estoppel landscape, since IPR2025-01353 was denied institution, statutory estoppel under 35 U.S.C. § 315(e)(1) applies to Guardant Health, Inc. and its privies. This prevents them from asserting, in other Office proceedings or civil actions, any ground that was raised or reasonably could have been raised in this IPR petition. For a defendant currently facing assertion by Cold Spring Harbor Laboratory who is not Guardant Health or its privy, all prior-art grounds remain available for potential PTAB challenge. The status of "Institution Denied" itself is not a pattern signal of aggressive PTAB appeals, as no appealable decision was reached. The fact that Guardant Health, a significant entity in the DNA sequencing field (known for challenging patents, e.g., US10760127), filed against this patent indicates that the patent is considered relevant to competitive technologies.

Recommended next steps

If you are a defendant facing assertion of US12234510, the denial of institution for IPR2025-01353 means the patent claims have not been substantively reviewed or narrowed by the PTAB. It is worth noting that Cold Spring Harbor Laboratory has an active district court case against Guardant Health, Inc. (Case: 25-263 in the District of Delaware), which was filed on 2025-10-10. This parallel litigation context may have played a role in the PTAB's discretionary denial, especially given recent changes in PTAB policies concerning such situations.

To fully assess the impact of IPR2025-01353, you should obtain and carefully review the PTAB's institution decision to understand the precise reasoning for its denial. This information is critical for identifying potential deficiencies in Guardant Health's petition and for formulating a stronger, more targeted challenge if you choose to pursue your own IPR. The decision document would provide details on the specific claims challenged, the prior art asserted, and the Board's analysis of the likelihood of success or any discretionary factors that led to the denial. Access to PTAB decisions is typically available through the USPTO PTAB Decisions portal, though specific case documents may require an E2E account.

Given the patent owner's success at the institution stage, any new IPR petition would need to demonstrate a clear likelihood of prevailing on the merits, potentially with different prior art or arguments, and address any discretionary factors that may have influenced the previous denial.